Related Experiment Video
Updated: Apr 17, 2026
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Can we use Sorafenib for advanced Hepatocellular Carcinoma (HCC) Child Pugh B?
K Rasul1, A Issameldin1, S Elazzazi1
1NCCCR, Hamad Medical Corporation, Doha, Qatar.
Insights
Sorafenib treatment improved survival for patients with advanced hepatocellular carcinoma (HCC), particularly those with Child-Pugh A liver function. This study highlights sorafenib
Area of Science:
- Hepatocellular Carcinoma (HCC) research
- Oncology
- Pharmacological treatments for liver cancer
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
- HCC incidence is rising in regions including Europe and the USA.
- Advanced HCC presents significant treatment challenges.
Purpose of the Study:
- To evaluate the safety and effectiveness of sorafenib in advanced HCC patients.
- To assess sorafenib outcomes in patients with Child-Pugh A and B liver function.
- To compare sorafenib efficacy in different liver function groups.
Main Methods:
- Retrospective observational study design.
- Inclusion of 46 patients with advanced HCC (Child-Pugh A and B).
- Patients had either failed or were ineligible for local palliative ablation therapy.
Main Results:
- Sorafenib was well-tolerated in both Child-Pugh A and B groups.
- Overall survival was improved with sorafenib treatment.
- Survival benefits were more pronounced in the Child-Pugh A group.
Conclusions:
- This study is the first to include a significant proportion (47%) of Child-Pugh B patients treated with sorafenib.
- Sorafenib demonstrated improved overall survival compared to international data for both Child-Pugh groups.
- Sorafenib represents a viable treatment option for advanced HCC across Child-Pugh A and B classifications.
Unlabelled:
HCC is the third cause of cancer-related death worldwide and the fifth most common cancer in the world with an increasing incidence in some areas like Europe, USA and the Gulf region. In this study patients with advanced HCC in both group child pugh A and B were treated with sorafenib.
Methods:
This is a retrospective observational study to assess the safety and effectiveness of sorafenib in patients with advanced HCC child pugh A and B who failed local palliative ablation therapy or were not eligible for such therapy. Forty six patients included.
Results:
In both child pugh A and B group the sorafenib was well tolerated and survival was improved but it was more pronounced in the child pugh A group.
Conclusion:
This is the first study that includes high percentage (47%) of child B group to be treated with sorafenib. Compared with international data there was improved overall survival in both groups.
